Brain Cancer Clinical Trials in Seattle

Showing 41-60 of 70 trials

Expanded Access Protocol Using 131I-MIBG

NCT01590680

Protocol JDI2007-01 is an Expanded Access Protocol with therapeutic 131I-MIBG for patients with neuroblastoma or pheochromocytoma / paraganglioma, who otherwise do not qualify for available treatments, or where approved treatment is not commercially available.

NeuroblastomaPheochromocytomaParaganglioma

Jubilant DraxImage Inc.

Los Angeles, California, United States • Aurora, Colorado, United States • Atlanta, Georgia, United States +16 more locations

COMPLETED< 1 mile

Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)

NCT02997423

This is a multi-institutional, consortium-based, non-interventional prospective blinded endpoints clinical study to determine whether high activity of Cytochrome C Oxidase (CcO) in tumor specimens from subjects with newly diagnosed primary GBM is associated with shortened OS (primary outcome) and PFS (secondary outcome) times.

Glioblastoma

University of Iowa153 participantsStarted Nov 2016

Birmingham, Alabama, United States • Sacramento, California, United States • Miami, Florida, United States +16 more locations

Expanded Access Protocol Using 131I-MIBG

Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)

Brain Cancer Trials in Other Cities

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

ANG1005 in Patients With Recurrent High-Grade Glioma

Radiation Therapy in Treating Young Patients With Gliomas

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor

Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme

Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

Gliogene: Brain Tumor Linkage Study

A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

Other Conditions in Seattle